Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of Involvement.

about

Outcome After Radiation Therapy for Langerhans Cell Histiocytosis Is Dependent on Site of Involvement.

Item

http://www.wikidata.org/entity/Q50056461

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Outcome After Radiation Therap ...... endent on Site of Involvement.

@en

Outcome After Radiation Therap ...... endent on Site of Involvement.

@nl

type

Item

label

Outcome After Radiation Therap ...... endent on Site of Involvement.

@en

Outcome After Radiation Therap ...... endent on Site of Involvement.

@nl

prefLabel

Outcome After Radiation Therap ...... endent on Site of Involvement.

@en

Outcome After Radiation Therap ...... endent on Site of Involvement.

@nl

P1476

Outcome After Radiation Therap ...... endent on Site of Involvement.

@en

P2093

Benjamin H Lok

http://www.w3.org/2001/XMLSchema#string

James Laird

http://www.w3.org/2001/XMLSchema#string

Jennifer Ma

http://www.w3.org/2001/XMLSchema#string

Karen Chau

http://www.w3.org/2001/XMLSchema#string

Monica Chelius

http://www.w3.org/2001/XMLSchema#string

Weiji Shi

http://www.w3.org/2001/XMLSchema#string

Zhigang Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net

Recurrent BRAF mutations in Langerhans cell histiocytosis

Langerhans Cell Histiocytosis: Emerging Insights and Clinical Implications

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Langerhans' cell histiocytosis in patients older than 21 years.

Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years

Risk factors for diabetes insipidus in langerhans cell histiocytosis.

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.

Radiotherapy in langerhans cell histiocytosis - a rare indication in a rare disease

Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?

P304

670-678

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJROBP.2017.10.053

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Joachim Yahalom

P577

2017-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29413280

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

5806138

http://www.w3.org/2001/XMLSchema#string